The company have significantly boosted the development of the novel treatment for amyloid heart disease, leveraging the investigational drug. Early patient information reveals promising outcomes for those diagnosed with https://biotech944461.qodsblog.com/42280123/bridgebio-progresses-amyloidosis-treatment-through-attruby